| Drug General Information |
| Drug ID |
D0T3ME
|
| Former ID |
DCL000071
|
| Drug Name |
BIRB 796
|
| Synonyms |
Doramapimod; BIRB796; BIRB-796; Doramapimod, BIRB 796; Doramapimod (USAN/INN); 1-(3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(morpholin-4-yl)ethoxy)naphthalen-1-yl)urea; 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea; 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA; 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl)urea; 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl)urea; 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
|
| Drug Type |
Small molecular drug
|
| Indication |
Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51]
|
Discontinued in Phase 2 |
[1],
[2]
|
|---|
| Company |
Boehringer Ingelheim
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C31H37N5O3
|
| InChI |
InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)
|
| InChIKey |
MVCOAUNKQVWQHZ-UHFFFAOYSA-N
|
| CAS Number |
CAS 285983-48-4
|
| PubChem Compound ID |
|
| PubChem Substance ID |
824691, 6594230, 7886048, 10252919, 14885325, 17397825, 46232236, 46392387, 46506062, 46513934, 50100090, 53400617, 53790487, 57348295, 57410867, 57551953, 85202069, 99226934, 103320031, 103904828, 104253223, 113435055, 119524695, 121619589, 124757348, 124950164, 125164152, 125504005, 126644894, 126671529, 128652222, 131287876, 131308895, 131539116, 134338774, 134345547, 135111840, 135697688, 136340220, 136349968, 136368041, 136920293, 137016667, 142526886, 143497500, 144115719, 144206937, 152238409, 152258171, 160647008
|
| Target and Pathway |
| Target(s) |
MAP kinase p38 |
Target Info |
Inhibitor |
[3],
[4]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Rap1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Oocyte meiosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Influenza A
|
|
Epstein-Barr virus infection
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FGF signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Signaling mediated by p38-gamma and p38-delta
|
|
Reactome
|
NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
VEGFA-VEGFR2 Pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Insulin Signaling
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Signal Transduction of S1P Receptor
|
|
Parkinsons Disease Pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
Integrin-mediated Cell Adhesion
|
|
DSCAM interactions
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5668). |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017152) |
|---|
| REF 3 | Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J. 2009 Mar 15;418(3):625-34. |
|---|
| REF 4 | Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009 Feb;60(2):317-20. |
|---|
